{
    "organizations": [],
    "uuid": "e99ccbe1d21d64f9e56addb3e7fa3fc5aeef435a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cellect-biotechnology-announces-cl/brief-cellect-biotechnology-announces-clinical-results-idUSFWN1OZ0MX",
    "ord_in_thread": 0,
    "title": "BRIEF-Cellect Biotechnology Announces Clinical Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 4, 2018 / 1:12 PM / Updated 10 minutes ago BRIEF-Cellect Biotechnology Announces Clinical Results Reuters Staff 1 Min Read \nJan 4 (Reuters) - Cellect Biotechnology Ltd: \n* CELLECT BIOTECHNOLOGY - ‍COMPLETED TRANSPLANTATION OF FIRST GROUP OF 3 PATIENTS USING CELLECT‘S APOGRAFT TECHNOLOGY IN CO‘S PHASE I/II CLINICAL TRIAL​ \n* CELLECT BIOTECHNOLOGY-‍AFTER 1 MONTH FOLLOW-UP, ALL 3 PATIENTS DEMONSTRATED ACCEPTANCE OF STEM CELL TRANSPLANT WITH NO ADVERSE EVENTS RELATED TO STUDY​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T15:11:00.000+02:00",
    "crawled": "2018-01-04T15:27:59.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "biotechnology",
        "announces",
        "clinical",
        "result",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "cellect",
        "biotechnology",
        "ltd",
        "cellect",
        "biotechnology",
        "transplantation",
        "first",
        "group",
        "patient",
        "using",
        "cellect",
        "apograft",
        "technology",
        "co",
        "phase",
        "clinical",
        "cellect",
        "month",
        "patient",
        "demonstrated",
        "acceptance",
        "stem",
        "cell",
        "transplant",
        "adverse",
        "event",
        "related",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}